1. Home
  2. VRTX vs COIN Comparison

VRTX vs COIN Comparison

Compare VRTX & COIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • COIN
  • Stock Information
  • Founded
  • VRTX 1989
  • COIN 2012
  • Country
  • VRTX United States
  • COIN United States
  • Employees
  • VRTX N/A
  • COIN N/A
  • Industry
  • VRTX EDP Services
  • COIN Finance: Consumer Services
  • Sector
  • VRTX Technology
  • COIN Finance
  • Exchange
  • VRTX Nasdaq
  • COIN Nasdaq
  • Market Cap
  • VRTX 96.6B
  • COIN 82.2B
  • IPO Year
  • VRTX 1991
  • COIN 2021
  • Fundamental
  • Price
  • VRTX $423.53
  • COIN $348.97
  • Analyst Decision
  • VRTX Buy
  • COIN Buy
  • Analyst Count
  • VRTX 26
  • COIN 28
  • Target Price
  • VRTX $491.78
  • COIN $359.70
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • COIN 9.5M
  • Earning Date
  • VRTX 11-03-2025
  • COIN 10-30-2025
  • Dividend Yield
  • VRTX N/A
  • COIN N/A
  • EPS Growth
  • VRTX N/A
  • COIN 90.38
  • EPS
  • VRTX 14.07
  • COIN 10.37
  • Revenue
  • VRTX $11,418,800,000.00
  • COIN $6,706,042,000.00
  • Revenue This Year
  • VRTX $10.92
  • COIN $19.30
  • Revenue Next Year
  • VRTX $9.55
  • COIN $13.52
  • P/E Ratio
  • VRTX $30.04
  • COIN $31.12
  • Revenue Growth
  • VRTX 10.46
  • COIN 49.18
  • 52 Week Low
  • VRTX $362.50
  • COIN $142.58
  • 52 Week High
  • VRTX $519.88
  • COIN $444.65
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 61.96
  • COIN 52.76
  • Support Level
  • VRTX $405.54
  • COIN $310.49
  • Resistance Level
  • VRTX $432.76
  • COIN $354.06
  • Average True Range (ATR)
  • VRTX 8.97
  • COIN 18.73
  • MACD
  • VRTX 1.62
  • COIN -3.67
  • Stochastic Oscillator
  • VRTX 71.05
  • COIN 41.98

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About COIN Coinbase Global Inc.

Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.

Share on Social Networks: